Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E20.95 EPS (ttm)2.66 Insider Own0.20% Shs Outstand1.67B Perf Week4.17%
Market Cap93.19B Forward P/E18.22 EPS next Y3.06 Insider Trans-5.01% Shs Float1.64B Perf Month-0.22%
Income4.46B PEG1.79 EPS next Q0.73 Inst Own72.60% Short Float1.43% Perf Quarter19.76%
Sales19.43B P/S4.80 EPS this Y184.60% Inst Trans0.01% Short Ratio2.16 Perf Half Y13.91%
Book/sh9.66 P/B5.76 EPS next Y9.18% ROA13.50% Target Price55.76 Perf Year-18.64%
Cash/sh3.79 P/C14.68 EPS next 5Y11.69% ROE29.20% 52W Range45.68 - 75.54 Perf YTD-3.42%
Dividend1.56 P/FCF- EPS past 5Y4.20% ROI20.00% 52W High-26.30% Beta1.09
Dividend %2.80% Quick Ratio1.40 Sales past 5Y-1.80% Gross Margin74.60% 52W Low21.87% ATR0.84
Employees25000 Current Ratio1.60 Sales Q/Q22.30% Oper. Margin30.80% RSI (14)64.57 Volatility1.55% 1.41%
OptionableYes Debt/Eq0.41 EPS Q/Q550.30% Profit Margin22.90% Rel Volume1.40 Prev Close53.77
ShortableYes LT Debt/Eq0.35 EarningsApr 27 BMO Payout57.00% Avg Volume10.92M Price55.67
Recom2.40 SMA203.93% SMA501.31% SMA200-1.19% Volume15,305,460 Change3.53%
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Apr-27-17 07:42PM  Oil's 'false tell' could set off domino effect CNBC Videos
07:01PM  Cramer: When Oil Falls, These Dominoes Get Hit
06:37PM  Cramer: How oil's 'false tell' could set off a market-cha... CNBC Videos
06:11PM  Cramer: How oil's 'false tell' could set off a market-changing domino effect CNBC
05:08PM  Strong Sales for Opdivo and Eliquis Drive Bristol-Myers' Solid Q1
05:02PM  Bristol-Myers Stock Pops On Street-Crushing Q1 Revenue, Profits Investor's Business Daily
04:48PM  AbbVie Flirts With Buy Point After Q1 Earnings, Sales Top Investor's Business Daily
03:05PM  Bristol-Myers: Not Dead Yet?
03:00PM  Bristol-Myers Stock Pops On Street-Crushing Q1 Revenue, Profits Investor's Business Daily
01:02PM  A Refreshing Voice At Bristol-Myers Squibb Forbes
12:07PM  Biopharma earnings bonanza CNBC Videos
11:01AM  Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View Zacks
10:34AM  Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo Reuters
09:53AM  US STOCKS-Wall St little changed with eyes on earnings Reuters
08:00AM  Bristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference Business Wire
07:36AM  Analysts Ratings and Recommendations for Bristol-Myers Squibb Market Realist
07:28AM  Bristol-Myers tops Street 1Q forecasts Associated Press
07:09AM  Bristol-Myers Squibb stock surges 3% after first-quarter profit, revenue beats MarketWatch
06:59AM  Bristol-Myers beats Wall St estimates, helped by Cancer drug Opdivo Reuters
06:59AM  Bristol-Myers Squibb Reports First Quarter Financial Results Business Wire
06:35AM  Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids
Apr-26-17 10:37AM  A Look at Bristol-Myers Squibbs Other Segments in 1Q17 Market Realist
09:09AM  Bristol-Myers Squibbs 1Q17 Estimates: Virology Segment Market Realist
08:04AM  Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY Zacks
07:37AM  A Look at Bristol-Myers Squibbs Oncology Segment in 1Q17 Market Realist
04:21AM  Moody's: Outlook for global pharmaceuticals industry stable on low earnings growth, new product launches Moody's
Apr-25-17 10:07PM  [$$] Aquinnah Pharmaceuticals Taps Pfizer, AbbVie for $10 Million The Wall Street Journal
06:06PM  Bristol-Myers Squibbs 1Q17 Estimates: Expect Growth! Market Realist
04:28PM  What Analysts Expect of Bristol-Myers Squibbs 1Q17 Earnings Market Realist
03:46PM  U.S. Supreme Court may limit where companies can be sued Reuters
03:09PM  U.S. Supreme Court may limit where companies can be sued Reuters
02:46PM  Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store? Zacks
01:00PM  Chill Pill: Eli Lilly Cuts Guidance with Earnings Investopedia
12:14PM  U.S. Supreme Court may limit where companies can be sued Reuters
08:04AM  3 Reasons Pfizer Is a Better Dividend Stock Than Bristol-Myers Squibb Motley Fool
06:05AM  America's 12 Most Charitable Companies Motley Fool
01:30AM  Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer Business Wire
Apr-24-17 01:52PM  NASH: The next untapped pharma market gives investors many options Reuters
09:06AM  3 Key Factors to Look Out for in Biogen's Q1 Results Zacks
07:00AM  NASH: The next untapped pharma market gives investors many options Reuters
01:00AM  NASH: The next untapped pharma market gives investors many options Reuters
Apr-22-17 01:01AM  Bristol-Myers Squibbs BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial Business Wire
01:00AM  Bristol-Myers NASH drug reduces liver fat in midstage study Reuters
Apr-21-17 02:06PM  Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer Business Wire
07:12AM  Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL Zacks
Apr-20-17 04:32PM  Is Bristol-Myers Prepping To Outdo Itself In Immuno-Oncology? Investor's Business Daily
10:47AM  Bristol-Myers Squibb Co: Buy the Dip? Motley Fool
Apr-19-17 05:03PM  Bristol-Myers 'Holding Up Better,' But Dow's Merck Still Gouging Share Investor's Business Daily
Apr-18-17 11:04AM  The 4 Best Dividend Stocks in Pharmaceuticals Motley Fool
10:08AM  Bristol-Myers and Nordic Ink Biomarker Collaboration Deal Zacks
08:22AM  Exelixis, Inc.: Time to Move On? Motley Fool
08:15AM  Blog Coverage Bristol-Myers and Nordic Announce an Agreement for Development of Fibrosis Biomarker Technology Accesswire
Apr-17-17 04:43PM  Top Research Reports for Alphabet, Amgen & Lowe's Zacks
09:37AM  Biogen to License Alzheimer Candidate from Bristol-Myers Zacks
06:59AM  Bristol-Myers Squibb and Nordic Bioscience Announce Collaboration for Fibrosis Biomarker Technology Business Wire
Apr-14-17 11:40AM  Bristol-Myers Squibb Co. : BMY-US: Dividend Analysis : April 07th, 2017 (record date) : By the numbers : April 14, 2017 Capital Cube
Apr-13-17 04:40PM  Could Bristol's Drug Help Biogen Take AbbVie In Alzheimer's? Investor's Business Daily
12:01PM  Morgan Stanley Ups Incyte Target to $150
10:20AM  Biogen pays $300M to Bristol-Myers for another potential Alzheimer's drug American City Business Journals
08:29AM  Bristol-Myers to license two drugs to Biogen, Roche Reuters
07:36AM  Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops Zacks
07:23AM  Bristol-Myers to license two of its drugs to Biogen, Roche Reuters
07:11AM  Bristol-Myers to get $470 million upfront for license deals with Biogen and Roche MarketWatch
07:00AM  Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb Business Wire
06:59AM  Bristol-Myers Squibb Enters into Separate Agreements with Biogen and Roche to License Anti-eTau and Anti-Myostatin Compounds, Respectively Business Wire
Apr-12-17 06:40PM  Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo Zacks
08:08AM  [$$] Incyte: Why This Biotech Beauty Can Stay Hot
Apr-11-17 03:03PM  3 Big Drugmakers Most Likely to Buy Incyte Motley Fool
06:59AM  Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors Business Wire
Apr-10-17 07:01PM  UK cost agency turns down Bristol drug for head and neck cancer Reuters
09:29AM  Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549 Zacks
Apr-07-17 03:05PM  How Bristol-Myers Squibb Stock Performed in 1Q17 Market Realist
Apr-06-17 09:57AM  Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA Zacks
Apr-05-17 02:38PM  Step Aside, Merck And Bristol: These Are Your Future Rivals In Cancer Drugs Investor's Business Daily
02:09PM  The Mutual Fund That Is a Top 10 Guru
Apr-04-17 04:48PM  Bristol Keeps Up With Merck In Cancer, But Incyte Is True Winner: Analyst Investor's Business Daily
04:15PM  U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibbs Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer Business Wire
12:01PM  Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo Zacks
11:17AM  Incyte Is Smart to Date Around Bloomberg
10:49AM  Bristol-Myers Opdivo Fails In Glioblastoma Study Investopedia
09:22AM  Bristol-Myers Melanoma Drug Combo Succeeds Investopedia
Apr-03-17 05:05PM  Bristol-Myers (BMY), Incyte to Advance Clinical Program Zacks
05:02PM  The Hot Stock: Incyte Jumps 3.6% at
04:20PM  Bristol 'Can't Afford To Lose' To Dow Stock Merck In Immuno-Oncology
03:33PM  [$$] Bristol-Myers May Be Hedging on IO at
11:07AM  Bristol-Myers Squibb says cancer drug combination 'significantly' improved survival in late-stage melanoma trial at MarketWatch
10:47AM  Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme Business Wire
08:30AM  Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) and Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma Business Wire
08:30AM  Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), in Phase 1 Study CA209-003 Business Wire
08:30AM  Bristol-Myers immunotherapy combination extends survival in melanoma
08:21AM  3 Stocks the Smartest Investors are Buying Right Now at Motley Fool
06:05AM  [$$] Merck's Keytruda cancer drug records sales surge at Financial Times
Apr-02-17 09:40AM  Bristol-Myers Squibb Trades Ex-Dividend Wednesday at Investopedia
07:23AM  5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them at Motley Fool
06:59AM  Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials Business Wire
Mar-31-17 04:23PM  Will Bristol Prove This Longtime Theory In Cancer Defense?
12:48PM  Merck, Incyte Expand Cancer Collaboration at
12:19PM  Novartis Focuses on Portfolio Prioritization to Boost Profitability
10:36AM  Exploring Eli Lillys Oncology Franchise in 2016
Mar-30-17 03:26PM  Should Investors Worry About Bristol-Myers Squibb's Recent Setbacks? at Motley Fool
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaborations with Portola Pharmaceuticals, Inc. to develop and commercialize andexanet alfa, an investigational agent; Apexigen, Inc. to evaluate Opdivo in combination with APX005M in patients with solid tumors; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDREOTTI LAMBERTODirectorApr 07Sale53.2217,000904,791935,571Apr 10 05:09 PM
ANDREOTTI LAMBERTODirectorApr 06Sale53.2917,000905,964952,571Apr 10 05:09 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554044,125Apr 04 07:17 PM
ANDREOTTI LAMBERTODirectorMar 28Sale56.2017,000955,369969,112Mar 29 06:19 PM
ANDREOTTI LAMBERTODirectorMar 27Sale56.1417,000954,451986,112Mar 29 06:19 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 17Sale56.495,000282,47021,483Mar 21 04:35 PM
Caldarella Joseph CSVP & ControllerMar 15Sale57.298,096463,77955,637Mar 22 06:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 14Sale56.7515,000851,22026,483Mar 16 04:37 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0087,6040199,229Mar 14 08:32 PM
Blin EmmanuelSVP, Chief Strategy OfficerMar 10Option Exercise0.0013,275023,690Mar 14 08:32 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0066,7260346,770Mar 14 08:33 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0065,4240451,862Mar 14 08:33 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,7210119,772Mar 14 08:31 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0025,592035,898Mar 14 08:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0087,3240289,293Mar 14 08:31 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.0013,696041,215Mar 14 08:30 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00102,17401,060,105Mar 14 08:30 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0031,513052,546Mar 14 08:29 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0018,799073,284Mar 14 08:29 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0033,271051,898Mar 14 08:30 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0015,484068,911Mar 14 08:29 PM
LEUNG SANDRAEVP, General CounselMar 06Sale57.0292,4055,268,563395,658Mar 07 04:39 PM
LEUNG SANDRAEVP, General CounselMar 03Option Exercise27.01116,1003,135,861488,063Mar 07 04:39 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise27.0122,598610,372212,516Mar 01 04:47 PM
Samuels Theodore R. IIDirectorFeb 27Buy56.7712,000681,24012,000Mar 01 04:47 PM
ANDREOTTI LAMBERTODirectorJan 30Option Exercise27.01100,0002,701,000957,931Feb 01 04:43 PM
Elicker John ESVP, Public Affairs & IRJan 03Option Exercise0.00950056,232Jan 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4030192,801Dec 06 04:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000187,794Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorNov 01Option Exercise22.14305,9096,772,825998,777Nov 03 05:22 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494055,505Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorOct 11Option Exercise17.51368,7066,456,042692,868Oct 13 05:00 PM
ANDREOTTI LAMBERTODirectorSep 08Sale56.9710,800615,276323,699Sep 09 04:41 PM
ANDREOTTI LAMBERTODirectorSep 07Sale56.7710,800613,116334,499Sep 09 04:41 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,596029,722Sep 07 04:33 PM
ANDREOTTI LAMBERTODirectorAug 25Sale58.9211,600683,472345,299Aug 25 05:10 PM
ANDREOTTI LAMBERTODirectorAug 24Sale59.4311,600689,359356,899Aug 25 05:10 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,511015,250Aug 03 04:56 PM
ANDREOTTI LAMBERTODirectorJul 08Sale75.0411,600870,461368,499Jul 11 05:12 PM
ANDREOTTI LAMBERTODirectorJul 07Sale73.8611,600856,776380,099Jul 11 05:12 PM
Blin EmmanuelSVP, Chief Strategy OfficerJul 02Option Exercise0.00951012,516Jul 06 05:58 PM
Cuss Francis MEVP & CSOJul 01Option Exercise0.003,6550291,628Jul 06 05:58 PM
Gordon MurdoEVP, Chief Commercial OfficerJul 01Option Exercise0.002,335014,950Jul 06 05:58 PM
ANDREOTTI LAMBERTODirectorJun 29Sale72.799,800713,342392,194Jun 30 05:42 PM
ANDREOTTI LAMBERTODirectorJun 28Sale71.6713,400960,396390,394Jun 30 05:42 PM
Elicker John ESVP, Public Affairs & IRJun 14Sale72.6911,820859,21955,011Jun 16 04:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMay 20Sale70.7930,2012,137,838184,694May 24 05:04 PM
Caldarella Joseph CSVP & ControllerMay 16Sale72.473,519255,00455,238May 17 04:46 PM
Caforio GiovanniChief Executive OfficerMay 05Option Exercise0.008,0400134,549May 09 04:42 PM
Caforio GiovanniChief Executive OfficerMay 03Option Exercise24.7950,4551,250,602145,958May 05 04:31 PM
Caforio GiovanniChief Executive OfficerMay 03Sale71.3134,5942,466,885117,118May 05 04:31 PM
ANDREOTTI LAMBERTODirectorMay 02Option Exercise26.04234,7206,112,787671,514May 04 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyMay 02Sale71.9522,2181,598,65221,971May 04 05:28 PM
ANDREOTTI LAMBERTODirectorMay 02Sale71.88234,72016,870,792436,794May 04 05:28 PM